A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome by Gruppen, Mariken P et al.
c l i n i ca l t r i a l www.kidney-international.orgOPENwith steroid-sensitive idiopathic nephrotic
see commentary on page 310A randomized clinical trial indicates that levamisole
increases the time to relapse in children
syndrome
Mariken P. Gruppen1, Antonia H. Bouts1, Marijke C. Jansen-van der Weide2, Maruschka P. Merkus3,
Aleksandra Zurowska4, Michal Maternik4, Laura Massella5, Francesco Emma5, Patrick Niaudet6,
Elisabeth A.M. Cornelissen7, Thierry Schurmans8, Ann Raes9, Johan van de Walle9, Mieke van Dyck10,
Ashima Gulati11, Arvind Bagga11 and Jean-Claude Davin1,8; all members of the Levamisole Study Group
1Department of Pediatric Nephrology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, The Netherlands; 2Pediatric
Clinical Research Office, Children’s Hospital/Academic Medical Center, Amsterdam, The Netherlands; 3Clinical Research Unit, Academic
Medical Center, Amsterdam, The Netherlands; 4Department of Pediatric and Adolescent Nephrology and Hypertension, Medical University
of Gdansk, Gdansk, Poland; 5Nephrology and Dialysis Unit, Pediatric Subspecialties Department, Bambino Gesù Children’s Hospital,
IRCCS, Rome, Italy; 6Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France; 7Department of Pediatric
Nephrology, Radboud University Medical Centre, Amalia Children’s Hospital, Nijmegen, The Netherlands; 8Department of Pediatric
Nephrology, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium; 9Department Pediatric Nephrology, Ghent University
Hospital, Ghent, Belgium; 10Department of Pediatrics, University Hospital, Leuven, Belgium; and 11Division of Nephrology, Department of
Pediatrics, All India Institute of Medical Sciences, New Delhi, IndiaLevamisole has been considered the least toxic and least
expensive steroid-sparing drug for preventing relapses of
steroid-sensitive idiopathic nephrotic syndrome (SSINS).
However, evidence for this is limited as previous
randomized clinical trials were found to have
methodological limitations. Therefore, we conducted an
international multicenter, placebo-controlled, double-
blind, randomized clinical trial to reassess its usefulness in
prevention of relapses in children with SSINS. The efficacy
and safety of one year of levamisole treatment in children
with SSINS and frequent relapses were evaluated. The
primary analysis cohort consisted of 99 patients from 6
countries. Between 100 days and 12 months after the start
of study medication, the time to relapse (primary endpoint)
was significantly increased in the levamisole compared to
the placebo group (hazard ratio 0.22 [95% confidence
interval 0.11–0.43]). Significantly, after 12 months of
treatment, six percent of placebo patients versus 26
percent of levamisole patients were still in remission.
During this period, the most frequent serious adverse event
(four of 50 patients) possibly related to levamisole was
asymptomatic moderate neutropenia, which was reversible
spontaneously or after treatment discontinuation. Thus, in
children with SSINS and frequent relapses, levamisole
prolonged the time to relapse and also prevented
recurrence during one year of treatment compared toCorrespondence: Mariken P. Gruppen, Emma Children’s Hospital, Pediatric
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510prednisone alone. However, regular blood controls are
necessary for safety issues.
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I diopathic nephrotic syndrome (INS) is a rare disease withan incidence that varies between 2 and 7 cases per 100,000children per year.1,2 It is hypothesized that INS results from
a defect in lymphocyte function.3 Most children with INS are
steroid sensitive. Seventy percent of the latter also
experience $1 relapses.1,2 Half of these children relapse
frequently after cessation of corticosteroids (frequently
relapsing nephrotic syndrome [FRNS]) or become steroid
dependent.4 Children with FRNS are then exposed to the side
effects of steroids.1,2 To reduce the relapse rate, several drugs
have been used.1,2 Among these, levamisole was considered
the least toxic and least expensive and the only one not
classified as an immunosuppressive agent until the pharma-
ceutical industry withdrew it from the market in 2004 for
human use due to lack of clear indications.5 Evidence of the
efficacy of levamisole in FRNS was restricted to retrospective
studies and a few clinical trials, all of which had some
methodological limitations.6–8 Since then, it has only
remained available as a low-cost drug for veterinary use, given
of its anthelminthic properties. We hypothesized that the
addition of levamisole following complete remission with
steroid therapy in children with FRNS or steroid dependencyKidney International (2018) 93, 510–518
MP Gruppen et al.: Levamisole increases the time to relapse in NS c l i n i ca l t r i a lwould either prevent relapses or prolong the time to relapse
during a 1-year treatment period.
For this reason, we conducted an international, multi-
center, double-blind, placebo-controlled, randomized clinical
trial (RCT) to assess the efficacy and safety of 1-year levam-
isole treatment in children with FRNS. Study medication
(levamisole or placebo) started during prednisone treatment
for a relapse. To study longer term efficacy and safety of
levamisole, patients still in remission and on levamisole




Between October 2007 and March 2012, 103 patients,
recruited from 13 sites in 6 countries (The Netherlands,
Belgium, France, Italy, Poland, and India), were randomized.
Ninety-nine patients were included in the modified intention-
to-treat population. Three randomized patients could not be
included because they did not start the study medication; for
2 of them, the study medication (placebo) did not arrive on
time, and proteinuria developed in the third patient (levam-
isole) before the start of study medication. One patient
(placebo) was excluded due to missing primary outcome
information. Eight patients prematurely discontinued study
medication (4 levamisole and 4 placebo) and were censored.
No patients were lost to follow-up (Figure 1). Nonadherence
with study treatment was not detected in any patient.
Demographic and baseline characteristics were similar
across both study treatment groups (Table 1). Analysis of age
and steroid dependency (SD) by region showed a similar age
distribution for both regions, but a difference in the distri-
bution of SD between Europe and India (Table 2). The range
and distribution of the lowest prednisone doses necessary to
prevent a relapse before the start of study are depicted in the
Supplementary Material Table S1.
Efficacy endpoints
Time to relapse (primary endpoint). Kaplan-Meier analysis
in the primary analysis (modified intention-to-treat) popu-
lation showed similar cumulative relapse-free survival prob-
abilities for both treatment groups during the first 100 days of
study medication (Figure 2). However, afterward, a difference
in the time to relapse became apparent in both treatment
groups in favor of the levamisole group (log-rank analysis,
total period, P ¼ 0.015). By the end of the 1-year study
period, 6% of placebo (3/49) versus 26% (13/50) of levami-
sole patients were still in remission and on study medication
(Figure 2). Since Kaplan-Meier curves showed that propor-
tional hazards could not be assumed throughout the 1-year
study period, a time-dependent Cox proportional hazards
regression analysis was performed incorporating the stratifi-
cation factors. During the first 100 days of study medication
similar hazards for a relapse needing prednisone were
observed in both treatment groups (hazard ratio [HR]: 1.14,
95% confidence interval [CI] 0.56–2.34, P ¼ 0.72).Kidney International (2018) 93, 510–518Afterward, a significantly lower hazard was observed in the
levamisole group compared with the placebo group (HR:
0.22, 95% CI 0.11–0.43, P ¼ 0.001) (Table 3). The HR was
not confounded by the prespecified covariates of sex, age, and
ethnicity. Exploratory subgroup analyses suggested insuffi-
cient evidence of treatment effect modification of the time to
relapse by region (India vs. Europe), SD (yes vs. no), sex, and
age (2–5 years vs. $6 years) (formal tests for treatment by
subgroup interaction; P values of 0.79, 0,64, 0.35, and 0.51,
respectively); see Kaplan-Meier curves for region and SD/FR
in the Supplementary Material Figures S1 and S2.
Occurrence of prednisone-needing relapse (secondary
endpoint). At 1-year follow-up, a lower cumulative propor-
tion of patients with a relapse requiring prednisone was seen
in the levamisole group (33/50, 66%) compared with the
placebo group (42/49, 86%) (relative risk estimate/crude
relative risk, 0.77; 95% CI 0.61–0.97; after adjustment for the
stratification variables, adjusted odds ratio was 0.30; 95% CI
0.11–0.82, P ¼ 0.02). Formal evaluation of effect modification
using treatment by subgroup interaction terms in multivari-
able regression models, including the stratification variables,
suggested insufficient evidence of heterogeneity of treatment
effect between these subgroups (Supplementary Material
Table S2).
Safety endpoints
In the safety population, more patients with at least 1 adverse
event (AE) were seen in the levamisole group versus the
placebo group (levamisole, 58% [29/50] vs. placebo, 38% [19/
50], p ¼ 0.045). However, the most clinically prominent AEs
were similar in both groups (pyrexia, nasopharyngitis, cough,
and mild neutropenia; 1000–1500 cells/ml in 3 patients of
each group). None of the latter required study discontinua-
tion (Table 4). Ten nonlethal serious AE occurred. They
included 5 cases of moderate neutropenia (500–1000 cells/ml)
(levamisole, 4/50 vs. placebo, 1/50) that were asymptomatic
and reversible after levamisole discontinuation (2/4 levami-
sole group) or spontaneously (2/4 levamisole group); 3 hos-
pitalizations (levamisole, 3/50 vs. placebo, 0/50), not related
with neutropenia; 2 levamisole patients presented with
reversible side effects after medication discontinuation, 1 with
a reduced glomerular filtration rate and 1 with arthritis and
antineutrophil cytoplasmic antibodies. With regard to the 4
levamisole patients with moderate neutropenia, in 2 of them,
neutropenia resolved without terminating levamisole and
both reached normal completion of the trial. The other 2
levamisole patients with neutropenia presented with a relapse
at the same time, so their primary endpoint was reached and
study medication was terminated. With respect to the 3
levamisole patients who required hospitalization (for high
fever in 1, pulmonary infection in 1, and abdominal pain in
1), 2 presented with relapse at the same time, so trial medi-
cation was discontinued, whereas the third patient did not
end trial medication but relapsed 8 months later (Table 4).
Comparison of laboratory values per visit (hemoglobin,
platelets, neutrophils, albumin, aspartate aminotransferase,511
Figure 1 | Randomization and follow-up of the study participants. *Normal completion: patients who were still in remission and on study
medication at 12 months after start study medication. **Longer term follow-up: to evaluate whether the effect of levamisole remained constant
or diminished over time and to assess side effects of long-term levamisole treatment; patients in remission at trial completion and still receiving
levamisole were followed for another 18 months (12 months with and subsequently 6 months without levamisole). ANCA, antineutrophil
cytoplasmic antibody; AST, aspartate aminotransferase; hep, hepatitis; mITT, modified intention-to-treat; RCT, randomized clinical trial.
c l i n i ca l t r i a l MP Gruppen et al.: Levamisole increases the time to relapse in NSand glomerular filtration rate), categorized as high, low, or
normal according to age, did not show any significant dif-
ference between the 2 treatment groups except at visit 3. At
that time, a significantly higher number of low glomerular512filtration rate values could be observed for the levamisole
group (P ¼ 0.03). The normal and abnormal values for the
glomerular filtration rate, neutrophils, and aspartate amino-
transferase according to time are shown in the SupplementaryKidney International (2018) 93, 510–518
Table 1 | Baseline characteristics of the modified intention-to-
treat population
Baseline
characteristics Placebo (N [ 49) Levamisole (N [ 50)
Cyclophosphamide,
N (%)a
3 (6) 3 (6)
Steroid-dependence,
N (%)








France 4 (8) 5 (10)
Rest of Europe 24 (49) 23 (46)
India 21 (43) 22 (44)
Sex, boys, N (%) 34 (69) 36 (72)
Ethnicity, N (%)
Caucasian 25 (51) 25 (50)
Black 2 (4) 0 (0)
Asian 21 (43) 23 (46)
Other 1 (2) 1 (2)
Missing 0 (0) 1 (2)
Age at presentation
of NS (yr), median
(IQR)
3.5 (2.25–5.75) 4 (2–5.25)
Age at randomization
(yr), mean (SD)
6.0 (3.1) 5.7 (2.6)
Duration disease (yr),c
median (IQR)
1 (0–2) 1 (0–2)
AD, alternate day; IQR, interquartile range; NS, nephrotic syndrome.
aPrevious cyclophosphamide treatment.
bLowest mean prednisone dose necessary to prevent a relapse before inclusion in
the randomized clinical trial.
cAge at presentation of newly diagnosed nephrotic syndrome.
Figure 2 | Relapse-free survival (Kaplan-Meier curve). The
cumulative proportion of patients in the modified intention-to-treat
population remaining in remission and on study medication over
time from the start of trial medication through a 1-year follow-up
period of the randomized clinical trial. The vertical bars on both
curves indicate study discontinuation for reasons other than relapse
(i.e., censored patients). L, levamisole; P, placebo.
MP Gruppen et al.: Levamisole increases the time to relapse in NS c l i n i ca l t r i a lMaterial Figures S3–S5. No difference in delta height between
baseline and 1-year follow-up was observed between the
levamisole and placebo groups (Supplementary Material
Figure S6).
Longer-term follow-up
Of the 13 levamisole patients who did not present with a
relapse during the year of the RCT, only 5 could subsequently
be included in the longer term follow-up extension of the trial
(Figure 1). Regarding the other 8 patients, all Indian, Indian
legislation did not allow import of study medication after
completion of the trial period because local Indian companies
have been producing levamisole for almost 3 decades. Of theTable 2 | Age and steroid dependence distribution in the








2–5 24 (43%) 23 (54%)
6–16 32 (57%) 20 (47%)
Steroid dependenceb
Yes 50 (89%) 18 (42%)
No 6 (11%) 25 (58%)
ac2 test, P ¼ 0.29.
bc2 test, P < 0.0001.
Kidney International (2018) 93, 510–5185 included patients, 1 had a relapse after 2 months and 1
stopped study participation after only 4 months (reason
unknown). The 3 remaining patients were treated with le-
vamisole for 12 months in the longer term follow-up without
a relapse; of those, only 1 was followed for 6 months after
levamisole cessation and did not relapse. One serious AE was
reported: asymptomatic neutropenia, <500 cells/ml, which
resolved after levamisole termination.DISCUSSION
This study shows that the addition of levamisole to standard
steroid therapy in children with FRNS increased the time to
relapse, after termination of prednisone treatment (100 days
post-randomization). Furthermore, it allowed 26% of
levamisole patients to be free of relapse for at least 1 year (vs.
6% in the placebo group). These results confirm the efficacy
of levamisole in FRNS, suggested previously by several
retrospective studies and 3 RCTs that had methodological
limitations to some extent.6–8 Two RCTs7,8 had unclear allo-
cation concealment, no blinding of patients and investigators,
insufficient statistical power, and inadequate relapse defini-
tions (i.e., not defined as a relapse necessitating prednisone
treatment). The British Association of Pediatric Nephrology
(BAPN) trial6 had adequate allocation concealment and was
double-blinded and placebo-controlled; however, levamisole
was given for only 4 months. In this study, more than half of513
Table 3 | Time to relapse (primary outcome) in the mITT








ratio (95% CI)a P value




















CI, confidence interval; mITT, modified intention-to-treat.
aHazard ratios were calculated using a time-dependent Cox proportional hazards
regression model with corresponding 95% confidence intervals. The hazard ratio can
be interpreted as the relative risk of the outcome at any fixed point in time.
bAdjusted for the stratification factors.
c l i n i ca l t r i a l MP Gruppen et al.: Levamisole increases the time to relapse in NSthe patients had received cyclophosphamide, which might
have biased the evaluation of levamisole effect because it has
been suggested that levamisole may be more effective in
patients previously treated with alkylating therapy.9 In the
latter trial, a difference in efficacy between the levamisole and
the placebo groups became apparent after 40 days, in contrast
to our trial in which a beneficial effect appeared after 100
days. The difference in efficacy between the BAPN and our
trial could be the result of a greater dosage and longer steroid
treatment in our study (cumulative prednisone dosage,
alternate days: BAPN trial, 24.5 mg/kg during 10 weeks vs.
levamisole trial, 2000 mg/m2 during 16 weeks). This is
illustrated by a higher percentage of control patients in
remission at 100 days in our study compared with the BAPN
study (percentage of control subjects in remission on day 100
in the levamisole trial was 70% vs. BAPN, <20%).Table 4 | Most frequently encountered SAEs in the safety
population
Levamisole (n/N) Placebo (n/N)
AEs




Neutropenia (1000–1500/ml) 3/50 3/50
SAEs
Neutropenia (500–1000/ml) 4/50 1/50
Neutropenia (<500/ml) 1/50
Hospitalizationb 3/50a 0/50
Reduced GFR 1/50 0/50
Arthritis/ANCAþ 1/50 0/50
AEs, adverse events; ANCA, antineutrophil cytoplasmic antibody; GFR, glomerular
filtration rate; SAEs, serious adverse events.
aPulmonary infection, fever, abdominal pain.
bP ¼ 0.045
514The currently observed increased efficacy of levamisole
after day 100 that coincided with the cessation of prednisone
might result from an increased metabolism and decreased
bioavailability of levamisole due to steroids as has been shown
for cyclosporine, tacrolimus, and sirolimus.10 Although
levamisole is not classified as an immunosuppressive agent,
investigation of possible metabolic and transporter pathways
with prednisone and duration of prednisone treatment,
regarding concentration levels, has not yet been investigated.
Exploratory descriptive analyses in separate subgroups
suggested possible differential treatment effects for subgroups
of the region and steroid dependency (Supplementary
Material Figures S1 and S2 and Table S2). However, formal
evaluation of effect modification using treatment-by-
subgroup interaction terms in multivariable regression
models, including stratification variables, suggested insuffi-
cient evidence of heterogeneity of treatment effect between
these subgroups. Looking at the distribution of SD patients in
the European subgroup compared with the Indian subgroup,
the greater majority of the European group (89%) involved
SD patients, whereas in the Indian subgroup, a proportion of
42% involved SD patients. This may have resulted in con-
founding, which is obscured in the descriptive within-
subgroups analyses. Moreover, these subgroup analyses
should be interpreted with much caution as these are
hampered by a lack of statistical power to adequately analyze
differential treatment effects between subgroups. This RCT
was only sufficiently powered to assess the overall treatment
effect. Additionally, the issue of multiplicity of testing, which
increases the probability of false-positive findings, related to
subgroup analyses should be acknowledged. Therefore, the
results of the exploratory subgroup analyses should only be
considered as a hypothesis-generating exercise, needing
establishment by future adequately powered RCTs.
So far, earlier RCTs on levamisole only included SD
patients6 or did not report the results of SD and frequently
relapsing patients separately.7,8
The smaller proportion of included SD patients in India
compared with Europe is consistent with a recent retrospec-
tive study from this country.11 It might be explained by
genetic predisposition and/or environmental factors.12,13 The
small proportion of frequently relapsing patients in the Eu-
ropean group may be explained by a more frequent use of the
French prednisone protocol for a relapse in Europe. In this
protocol, relapse treatment includes 4 months of steroids on
alternate days in addition to the period of daily treatment
until remission. Following this protocol, it is practically
impossible to fit with the definition of frequently relapsing
that requires at least 4 relapses per year, even if the protocol is
adapted individually.
In the safety population, asymptomatic and reversible
neutropenia was reported in 4 placebo patients (4/50, 8%)
and in 7 levamisole patients (7/50, 14%) (3 mild and 4
moderate cases) during the RCT year as well as in 1 patient
(severe) in the longer term follow-up phase. All patients were
asymptomatic and reversible after discontinuation of the drugKidney International (2018) 93, 510–518
MP Gruppen et al.: Levamisole increases the time to relapse in NS c l i n i ca l t r i a lor spontaneously in 2 patients. Although complete blood
counts were obtained every 2 to 4 weeks6,7 or 3 times a
month,8 neutropenia was not reported in 3 other RCTs.6–8 In
7 cohort studies (2 RCTs and 5 cohort studies), largely from
Middle East countries and India, neutropenia was only
reported in 8 of a total of 573 included patients in these
studies.14–20 Most of these studies checked the blood counts
on a regular basis (biweekly or monthly), but Dayal et al.8 and
Ekambaram et al.15 analyzed blood counts every 3 months.
Madani et al.,17 who included the majority of the patients
(304/573 patients), did not report the frequency of follow-up
visits. Because neutropenia during levamisole treatment could
be reversible and present without clinical symptoms, neu-
tropenia could have been missed in these studies.8,15,17
The strengths of our trial include the international,
multicenter, double-blind, placebo-controlled comparison of
1-year levamisole treatment in a large sample of a relatively
rare disease population. The compliance with study medica-
tion was regularly controlled, and nonadherence was not
detected in any patient. However, some limitations of our trial
must be noted. A few patients discontinued study medication
prematurely for other reasons than a relapse and were
censored. However, because this concerned only a few and
equal number of patients in both study groups (4 in each
group), we believe that the eventual influence of informative
censoring on the estimated treatment effects can be assumed
to be minimal. Because only 5 levamisole patients could be
included in the longer term follow-up phase, this study lacks
information on the long-term efficacy and safety of levami-
sole. Unfortunately, information on the cumulative steroid
dose and the number of patients who were evaluated for
eligibility but did not meet the eligibility criteria or who met
the eligibility criteria but declined to be enrolled is lacking. It
should be noted that this investigator-initiated, international
pediatric trial lacked financial resources to fund designated
local research staff to assist the investigators, who conducted
this study on a voluntary basis in addition to their busy day-
to-day clinical practice.
Patients with FRNS often need to be treated for many years
with different steroid-sparing agents. It is reasonable to start
with the drug with the best efficacy versus safety profile.
Because of a high rate of diverse serious side effects, it is
obvious that calcineurin inhibitor agents should be reserved
only in case of the failure of other drugs. Cyclophosphamide
was the first agent to be successfully used as a steroid-sparing
agent. A meta-analysis of RCTs comparing levamisole and
cyclophosphamide did not show a clear difference in efficacy
and side effects except for a prolonged treatment effect after
drug discontinuation of cyclophosphamide but not levami-
sole.21 However, a meta-analysis concludes that cyclophos-
phamide use in steroid-sparing INS is associated with a higher
risk of leucopenia (1 in 3 risk) and that oligospermia cannot
be excluded for any dose of cyclophosphamide.22 To the
best of our knowledge, until now, there was no study
comparing levamisole with mycophenolate. Levamisole is not
an immunosuppressive drug but an immunomodulatorKidney International (2018) 93, 510–518and immunostimulant. It is particularly important for chil-
dren needing prolonged courses of different steroid-sparing
agents in order to reduce the side effects of cumulative
immunosuppression.
To summarize, addition of levamisole to steroid therapy
led to prolongation of time to relapse in children with FRNS
from 5 European countries and India. Neutropenia was the
most frequently observed adverse effect but was always
asymptomatic and reversible spontaneously or with levami-
sole discontinuation. Other very rare, severe levamisole side
effects previously reported in the treatment of INS, including
hepatitis, convulsions, and antineutrophil cytoplasmic anti-
body vasculitis, were not observed in this study. However, an
antineutrophil cytoplasmic antibody–associated arthritis
reversible with levamisole discontinuation was observed in 1
patient. An unexpected and unexplained reduction of the
creatinine clearance that was immediately and completely
reversible after discontinuation of the drug was also observed
in 1 patient.
Because regular blood controls allowed early detection
and reversibility without complications of all levamisole-
related side effects, this trial justifies the use of levami-
sole as the first second-line drug in children with
FRNS to prevent relapses and lessen the complications of
steroids.
Future adequately powered trials should be performed to
evaluate the efficacy and safety of levamisole in subgroups of
FRNS (i.e., without and with different degrees of steroid
dependence).
METHODS
Trial design and oversight
We performed an international, multicenter, placebo-controlled,
double-blind, randomized clinical superiority trial, followed by a
longer term follow-up study to evaluate the efficacy and safety of
levamisole in children with INS.
Ethical approval of the study protocol was obtained from the
Institutional Review Boards of each participating institute. The study
was prospectively registered in international trial registers (Eudra-
CT/EMA register 9/2007, Eudra CT 2005-005745-18, NTR1769,
ISRCTN 23853712).
Details on design and oversight are provided in the Supple-
mentary Material (item 2).
Patients and participating centers
FRNS children with or without steroid dependence (SD, FR), 2 to 18
years of age were eligible for the study. FRNS was defined as $2
relapses occurring within 6 months of the initial response or $4
relapses occurring in any 12-month period; SD was based on the
report of any lowest prednisone dose needed to prevent a relapse
before inclusion in the trial (Table 5).
Exclusion criteria included NS with kidney disease, neu-
tropenia, convulsions, hepatic disease, unresponsiveness to cyclo-
sporine or mycophenolate mofetil, prolongation of the Qtc interval
on surface electrocardiography (>0.44 s) at presentation, preg-
nancy, breastfeeding, participation in another trial as well as those
patients previously treated with levamisole. Patients were recruited
from 13 academic hospitals in 6 countries, including The515
Table 6 | Prednisone treatment of steroid-sensitive nephrotic
syndrome relapse
Dosage Period of use
60 mg/m2 once daily Once daily until urine is protein free for 6–8 days
60 mg/m2 once daily Every other day for 4 weeks
45 mg/m2 once daily Every other day for 4 weeks
30 mg/m2 once daily Every other day for 4 weeks
15 mg/m2 once daily Every other day for 4 weeks
Corticosteroids at inclusion are given according to the national French protocol for
treatment of a relapse of steroid-sensitive nephrotic syndrome (www.soc-
nephrologie.org).
Table 5 | Definitions
Condition Diagnostic criteria
Adverse event Any adverse change in condition between the time of informed consent and end of the trial
Idiopathic nephrotic syndrome Nephrotic range proteinuria (urinary proteins >200 mg/mmol creatinine) with hypoalbuminemia (serum
albumin <25 g/l) without signs of a specific etiology (e.g., Henoch-Schoenlein purpura, acute post-infectious
glomerulonephritis)
Frequent relapses $2 relapses occur within 6 months of initial response or when $4 relapses occur in any 12-month period
Neutropenia According to the protocol, we stopped the study medication for an absolute neutrophil count <1500/ml; a
neutrophil count of <1000 cells/ml was considered an SAE. Mild neutropenia: >1000 and <1500 cells/ml.
Moderate neutropenia: >500 and <1000 cells/ml. Severe neutropenia: <500 cells/ml.
Prolonged Qtc Heart rate–corrected QT interval (QTc) >0.44 seconds, calculated with Bazett’s formula
Remission Proteinuria is <20 mg/mmol creatinine or at most a trace of protein when tested by dipstick on at least 3
consecutive days
Serious adverse event Any untoward medical occurrence or effect that at any dose:
- results in death
- is life threatening
- requires hospitalization or prolongation of existing inpatients’ hospitalization
- results in persistent or significant disability or incapacity
- is a congenital anomaly or birth defect
Any other important medical event that may not result in death or be life threatening or require hospitalization
may be considered a serious adverse experience when, based on appropriate medical judgment, the event may
jeopardize the subject or may require an intervention to prevent one of the outcomes listed.
Steroid dependence Relapse occurs during prednisone reduction or within 2 weeks after corticosteroid cessation.
Steroid dependency is based on any reported lowest prednisone dose needed to prevent a relapse before
inclusion in the trial.
Steroid-sensitive nephrotic
syndrome
Treatment of idiopathic syndrome with corticosteroids that leads to remission.
c l i n i ca l t r i a l MP Gruppen et al.: Levamisole increases the time to relapse in NSNetherlands, Belgium, France, Italy, Poland, and India. Before
enrollment, written informed consent to participate in the study
was obtained from all patients and/or their parent(s)/legally
acceptable representative.
Randomization and blinding
Patients were randomly allocated, when their urine was protein free
for 1 day and after signing the informed consent, to 1 of the 2 study
medications by a computerized random number generator in a 1:1
ratio. The randomization was stratified by SD (yes/no), previous use
of cyclophosphamide (yes/no), and region (France, other European
countries, India). Within the strata, the randomization procedure
was blocked. Patients, parents, investigators, medical and nursing
staff, outcome assessors, monitors, and data analysts were blinded to
study medication. Randomization data were kept strictly confidential
and accessible only to authorized persons.
Study intervention and procedures
Prednisone was started at the relapse of nephrotic syndrome, ac-
cording to dosage and tapering in steroid-sparing INS treatment
protocol of the French Society of Pediatric Nephrology (Table 6).
This protocol was chosen, due to the absence of an internationally
accepted guideline. Our choice was based on a meta-analysis sug-
gesting that longer steroid treatments and higher cumulative dosage
would be expected to better reduce the risk of relapse in steroid-
sparing INS.23 Levamisole or a matched placebo was started at
remission after at least 3 days, but not later than 21 days. The long
interval was necessary to distribute the study medication to India.
Levamisole was given orally as a tablet at 2.5 mg/kg on alternate
days, with a maximum dose of 150 mg. In order to obtain accurate
dosing in all children, 4 tablet strengths had been formulated (i.e.,
tablets containing 5, 10, 25, and 50 mg of levamisole.24 Proteinuria
was checked once a week by the parents by means of dipstick and
also in case of infection or clinical edema.516Individual unblinding took place when a relapse occurred (to give
patients in the placebo group the possibility of receiving levamisole)
or at the end of the 12-month trial.
Treatment was discontinued when the primary outcome was
reached, in case of a serious AE, or at the patient’s request. When a
relapse occurred before 1 year of follow-up, clinical follow-up was
done every 3 months for 1 year from the start of study medication.
Individual patient trial medication compliance was checked by
the investigator every 3 months, along with the number of dispensed
and returned tablets, using a drug accountability form.
More details on the study intervention and visits are given in the
Supplementary Material (item 3, Tables S3 and S4).
Outcome measures
Time to relapse (primary endpoint). The primary endpoint
was the time to relapse (i.e., the time between the start of study
medication and the occurrence of a relapse). Patients who did not
experience a relapse during the 1-year follow-up period of the RCT
were censored at 1 year after the start of study medication. Only a
relapse necessitating prednisone treatment was considered a primary
endpoint relapse.Kidney International (2018) 93, 510–518
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endpoint). The key secondary outcome concerned the cumulative
number of study discontinuations for a relapse needing prednisone
during the 1-year RCT.
Safety outcomes. Safety was assessed by analysis of adverse
events in both study medication groups and included laboratory
investigations, physical examination, and electrocardiography.
Longer term follow-up
To evaluate whether the effect of levamisole remained constant or
diminished over time and to analyze side effects of long-term
levamisole treatment, patients in remission at trial completion and
still receiving levamisole were followed for another 18 months (12
months receiving levamisole and 6 months without it).
Statistical analysis
Based on a meta-analysis a clinically relevant relative relapse risk of
0.60 during 1 year of levamisole treatment compared with placebo
was expected (proportion of relapse with prednisone treatment alone
75% vs. 45% with levamisole).25 Forty-two patients per treatment
arm were sufficient to demonstrate such an effect, with a 2-sided
significance level of 0.05 and a power of 80%. To allow for with-
drawal (generally 10%–20%), we aimed to include 50 patients per
arm.
The primary analysis population consisted of all patients who
received at least 1 dose of the study medication (active or placebo)
excluding 1 patient for whom information on the primary outcome
was missing (i.e., modified intention-to-treat). The inclusion regions
were compared regarding age (2–5, >5 years) and steroid depen-
dence (yes, no) using the c2 test. Region was categorized as Europe
and India because of the small number of patients included in
France. A Kaplan-Meier survival curve was drawn to compare the
primary outcome, time to relapse needing prednisone treatment in
both treatment groups, and to check the proportional hazards
assumption. A multivariable Cox proportional hazards analysis was
performed to determine the effect of levamisole compared with
placebo on time to relapse, expressed as a HR with a 95% CI,
incorporating the stratification factors (SD, previous use of cyclo-
phosphamide, region). In a secondary analysis, potential con-
founders (age, sex, and ethnicity) were tested. In addition,
exploratory subgroup analyses were conducted to investigate effect
modification of SD, region, sex, and age using treatment by subgroup
interaction terms in the Cox proportional hazards model.
Only 6 patients with previous use of cyclophosphamide were
included (Table 1), and therefore treatment effect modification by
cyclophosphamide could not be adequately analyzed. Statistical tests
of interaction terms directly examines the strength of evidence of the
treatment difference varying between subgroups.26,27 Patients who
prematurely stopped the study medication due to an adverse event or
other reasons were censored. Because the Kaplan-Meier curve
showed that the proportional hazards assumption was not met, a
time-dependent Cox regression analysis was conducted in which a
time-dependent covariable was entered into the model as an effect
modifier, and HRs were presented separately before and after 100
days post-randomization, the point at which the survival curves
crossed.
For the occurrence of a prednisone-needing relapse, the effect
estimate of levamisole versus placebo was calculated and expressed as
a crude relative risk and an adjusted odds ratio after adjustment for
the stratification variables using a logistic regression model. Statis-
tical uncertainty of these estimates was expressed with 95% CIs.Kidney International (2018) 93, 510–518A P value was obtained using a c2 test. Exploratory subgroup ana-
lyses were performed using formal tests of treatment by subgroup
interaction terms in logistic regression models including the strati-
fication variables.
All subgroup analyses should only be considered exploratory,
yielding hypothesis-generating findings because the trial was not
powered to adequately test subgroup effects and to allow adjust-
ments for multiple testing related to the subgroup analyses.
The safety analysis was performed in the safety population (i.e.,
patients who received at least 1 dose of the study drug). A c2 or
Fisher exact test was used as appropriate. Details on the safety
analysis procedure are given in the Supplementary Material (item
1d).
All statistical analyses were performed with SPSS Statistics for
Windows version 22 (IBM Corp., Armonk, NY).
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Table S1. Distribution of the lowest prednisone dose necessary to
prevent a relapse in steroid-dependent patients at randomization.
Figure S1. Kaplan-Meier curve for relapse-free survival according to
region subgroups (Europe and India). This figure shows the cumula-
tive proportion of patients in the modified intention-to-treat popu-
lation (mITT) according to region subgroups (Europe and India)
staying in remission and on study medication over time from the start
of the trial medication during a 1 year follow-up period of the RCT.
Treatment by region interaction effect, P ¼ 0.79 (see Results and
Discussion section). Exploratory subgroup analyses were performed
and statistically tested with interaction effects of the specific sub-
group and treatment in Cox proportional hazards regression models
including the stratification variables. Statistical tests of interaction
terms directly examine the strength of evidence for the treatment
difference varying between subgroups [1,2]. This subgroup analysis
should only be considered exploratory, yielding hypothesis-
generating findings since the trial was not adequately powered for
subgroups analyses and to allow adjustments for multiple testing
related to subgroup analyses.
Figure S2. Kaplan-Meier curves for relapse-free survival in patients
with SD or FR. This figure shows the cumulative proportion of patients
in the modified intention-to-treat population (mITT) in patients with
steroid dependency (SD) and frequent relapse (FR). Treatment by
steroid dependency interaction effect, P ¼ 0.64 (see Results and
Discussion section). Statistical tests of interaction terms directly
examine the strength of evidence for the treatment difference517
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were performed and statistically tested with interaction effects of the
specific subgroup and treatment in Cox proportional hazards
regression models including the stratification variables. This subgroup
analysis should only be considered exploratory, yielding hypothesis-
generating findings since the trial was not adequately powered for
subgroups analyses and to allow adjustments for multiple testing
related to subgroup analyses.
Table S2. Number of patients with a prednisone needing relapse
during the 1 year follow-up period of the RCT according to explor-
atory subgroups in the modified intention-to-treat (miTT) population.
Figure S3. Glomerular filtration rate according to time. This figure
shows the fraction of patients presenting with a GFR < 80 ml/min per
1.73 m2 according to the method of Schwartz [3] at each RCT visit for
levamisole (L) and placebo (P) groups. The number of patients
assessed per visit is mentioned at the top of each column. The
number of visits is included at the bottom of each column. A
decreased GFR was observed at different times in the L group, but
mainly at visit 3 (2 weeks after start of L). The lowest GFR observed
was 52 ml/min per 1.73 m2. Several low GFR values were observed
during a relapse. In all other cases, no cause could be found, with
spontaneous recovery occurring except in 1 patient, who recovered
completely 5 days after L discontinuation for a GFR ¼ 65.21 ml/min
per 1.73 m2.
Figure S4. Neutrophil values according to time. This figure shows the
percent of patients with neutropenia (neutrophils < 1500/ml) at each
RCT visit for levamisole (L) and placebo (P) groups. In the L group,
neutropenia was observed in 7 patients, from whom 4 had 500–1000
neutrophils/ml, and 3 patients had 1000–1500 neutrophils/ml. Those
values were distributed from visit 5 to 15 without any clear-cut
temporal pattern.
Figure S5. Aspartate aminotransferase values according to time. This
figure shows the percent of patients with high plasma values of
aspartate aminotransferase (>40 IU/l) at each RCT visit for levamisole
(L) and placebo (P) groups. High values have been observed at
different moments in the L group, but mainly at visit 7. One patient
with hepatitis B displayed values above 1000 IU/l. Several other
patients presented moderately increased values, remaining under
100 IU/l.
Figure S6. The delta-height (height measured at visit 1[baseline] and
visit 15 [1-year follow-up] in the levamisole and placebo group). This
figure shows change in height (mean with 95% CI) between baseline
(visit 1) and 1-year of follow-up (visit 15) in both study medication
groups for patients who had a height measurement at both time
points (placebo, n ¼ 39; levamisole, n ¼ 43). Delta height in levam-
isole verses the placebo group (mean, 95% CI): 6.86, 95% CI [6.03–
7.69] versus 6.28, 95% CI [5.38–7.18], P ¼ 0.88. Since 1-year height
data were not available for all patients, this result needs to inter-
preted with caution and remains to be established in long-term
studies.
Table S3. Summary of the levamisole trial protocol.
Table S4. Study visits.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.REFERENCES
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